The Pancreatic Cancer Collective has awarded a total of $7 million in first-round “New Therapies Challenge” grants to seven teams of top cancer researchers to explore new pancreatic cancer treatments.
To find the right cure for blood vessel diseases, researchers are working to design technology to predict the workings of vascular diseases and responses to drugs at a patient-specific level.
In a recent study, researchers combined clinical and laboratory studies to show the PPM1D gene can confer blood cells exposed to the chemotherapy agent cisplatin a survival advantage that might favor the development of leukemia years later.
Using a new grant from the Leukemia and Lymphoma Society, a team from Baylor College of Medicine will work to develop more widely applicable targeted cellular therapies for leukemia and lymphoma.
To better understand a predisposition for acute lymphoblastic leukemia in children with Down syndrome, a team of researchers will sequence the genomes of more than 2,000 individuals with Down syndrome.
In a review published in New England Journal of Medicine, physician-scientists review the history of Langerhans-cell histiocytosis (LCH) and the recent developments that will help propel the treatment for patients into the realm of personalized medicine.
Dr. Andras Heczey and Dr. Leonid Metelitsa received a $1.5 million grant from Alex’s Lemonade Stand Foundation to conduct a first-in-human Phase 1 Neuroblastoma clinical trial.
Baylor College of Medicine has received a Rally for Research Grant from the Rally Foundation for Childhood Cancer Research to support Dr. Tsz-Kwong (Chris) Man and his research in targeting methylome in chemo-resistant osteosarcoma.
